abbott enjoy benefit wax product cycl
updat forecast estim apr
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim apr
price data jul
rate updat jul
currenc amount express
valuat growth profit
methodolog valu compani
abbott continu remodel acquisit st jude
medic continu improv profit
segment nutrit devic diagnost establish
pharmaceut although abbott made progress sinc
spin-off still lag key rival profit measur
despit compet busi character
abbott effort improv effici includ streamlin
distribut channel build facil lower-cost locat
like china india demonstr success
still room improv look compani
consolid profit think abbott emphasi margin
improv pay next five year
like manag turn attent new sourc
growth view abbott new freestyl libr blood glucos
monitor offer compel innov anticip
addit veropharm provid abbott
substanti footprint latin america russia establish
applaud sale abbott epp busi develop market
reshuffl put abbott favor posit
benefit stronger demand brand gener emerg
market addit st jude along smaller tuck-in
rais firm abil compet hospit client seek
still forecast mid-single-digit revenu growth abbott
think potenti firm goos growth key
product line meantim see opportun
abbott enhanc effici fuel earn growth address
situat
larg
manag control abbott exceed expect
close profit gap competit set upsid
valuat
low-hang fruit
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
abbott manufactur market medic devic blood glucos
monitor kit nutrit healthcar product diagnost product
equip brand gener drug product includ pacemak
formula nutrit liquid adult vessel closur devic lasik
equip abbott deriv approxim sale outsid unit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
valuat growth profit apr
bump fair valu estim per share
increas estim domest
launch freestyl libr suit mri-compat
implant cardiovert defibril on-going adopt
alin system comprehens test panel
stabil infant formula market china
new regulatori hurdl process obtain infant
formula clearanc china somewhat pain
number
competitor expect benefit
abbott maintain optimist expect growth
electrophysiolog neuromodul product
thank new product launch underli
growth demand expect manag abl
meet goal million cost synergi year four
project approxim revenu growth
fuel acquisit aler averag annual
sale growth
regul
still see potenti improv profit abbott
remain busi turn key factor
valuat consolid basi abbott oper
margin significantli trail key competitor
variou busi segment good news abbott
compet sever market offer rel high
margin includ nutrit brand gener drug
cardiovascular devic addit abbott alreadi
begun effort improv product effici
streamlin distribut channel build new facil
lower-cost locat like china india expect
abbott partial close oper margin gap
project basi point improv firm
leverag distribut infrastructur built
penetr emerg market across product
segment extract cost synergi recent
bullish scenario put abbott valu per
share case assum abbott averag
top-lin growth thank addit st jude aler
well outsiz gain pediatr adult nutrit
intern double-digit growth molecular diagnost
greater penetr cardiovascular devic oversea
also assum abbott reach level manufactur
expens compar key competitor like dr
reddi along oper margin
peak
bear case abbott per share
scenario top line averag annual follow
addit st jude aler howev assum
declin stent sale
offer superior technolog long haul mute
perform
low-single-digit growth nutrit low-single-digit
growth diagnost assum abbott rais
gross margin basi point
portico
think addit st jude push abbott toward
wider side narrow moat fulli convinc
abbott tip wide moat categori
especi firm nurtur kind on-going
occasion revolutionari innov necessari
secur reimburs longer term
case abbott one three four competitor
domin market includ nutrit cardiac
monitor coronari stent immunoassay
market abbott particip ration oligopoli
enjoy benefit intang asset
think nutrit busi one moatiest
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
market often lack well-develop infrastructur
distribut instead abbott must sell product directli
pharmaci chain physician result brand
recognit reput key factor abbott
leverag sell fragment market also translat
less price pressur abbott could chang
longer term emerg market turn
tender system character develop nation
howev chang remain
near medium term think abbott benefit
addit st jude impress expertis
cardiac rhythm manag structur heart heart
failur howev juri still abbott abil
nurtur renew innov area long haul
abbott demonstr compet launch
next-gener product lifeblood devic
busi less enthusiast attempt
greater leap innov
final abbott reli intellectu properti ward
competitor devic diagnost segment
think firm earn narrow moat four
segment translat narrow moat entir
potenti price pressur variou sourc
across abbott market exampl trend toward
brand gener declin
reimburs vascular devic firm
invest pipelin lead stream new
product fortifi price power medium
term abbott scale divers help steadi moat
trend anticip strength cardiac devic segment
divis diabet busi off-set
current weak intern nutrit molecular
part new abbott wield leadership posit
highli consolid market estim
billion world-wide asid strength develop
market firm face brighter growth prospect
emerg market growth middle-class
famili spur demand pediatr adult nutrit
product thank strong similac ensur brand
abbott advantag posit introduc new
formul line extens penetr new
market abbott made substanti invest earli
build infrastructur emerg market includ
new ventur new zealand-bas build
large-scal dairi farm hub china firm
reap reward invest expand
build block experi nutrit
also play well appli abbott
establish pharmaceut product segment
mainli sold outsid busi frequent call
brand gener oper like consum busi
tradit brand drug exampl abbott
brand gener mainli sold less develop
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
abbott abil deploy robust predict cash
flow
busi toward acquisit
partnership help replenish pipelin
support abbott growth also keep smaller
compani gain critic mass encroach
abbott narrow moat abbott develop
revolutionari devic pipelin candid demonstr
strongli favor clinic outcom acquir
extens collect med-tech product allow
comprehens partner hospit
consid turn moat trend rate posit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oabbott xienc stent remain powerhous
well-
drug-elut stent market thank
establish record safeti efficaci
oaggress cost-cut plan propel abbott
bottom-lin growth quickli top-lin growth
oabbott sale establish pharma busi
develop market acquisit
veropharm put abbott brand gener
busi strong posit benefit grow
demand emerg market
oclin data drug-elut stent altern
therapi put crimp percutan coronari
procedur medic therapi coronari bypass
gain favor
oabbott face uphil battl molecular
diagnost arena must go head-to-head
market leader roch along energet
upstart like
oconsid heterogen involv mitral valv
diseas skeptic mitraclip move
beyond nich use certain inoper patient
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
larg acquisit st jude medic aler
abbott enjoy less financi flexibl
medium term issu debt share financ
purchas sale vision-car busi
stake abbott debt/ebitda hover around
end manag indic abbott
plan de-lever near term think
bring debt level closer time end
despit increas interest expens anticip
abbott
coverag
ebitda/interest time coverag
rise ensu year
abbott nutrit unit seem larg impervi
econom cycl think addit st jude increas
abbott exposur vagari cardiac product cycl
clinic trial reimburs issu accordingli
peg abbott uncertainti medium like compani
involv medic technolog abbott vulner
threat revolutionari innov competitor
particularli issu medic devic
diagnost busi despit abbott recent effort
better insul recal like infant formula
recal china risk product qualiti issu
recal remain damag firm brand
relationship medic profession hospit
custom payer tighten purs string abbott could
see greater price pressur furthermor hospit
cardiac therapeut area abbott could find
disadvantag compar key rival
johnson johnson final abbott oper
scrutini food drug administr
well regulatori agenc oversea lead
delay product approv product
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
va collegeamerica invmt co america
va collegeamerica growth fund america
new york mellon corp
share
fund
share
fund
overal rate abbott stewardship standard
compani made impress purchas
past decad includ purchas
billion brought humira sever
recent acquisit advanc medic optic
piram remain promis yet fulli match
purchas price remain skeptic acquisit
aler point-of-car diagnost seem
add compel valu abbott technolog
distribut bargain posit proprietari
pharma product spun expect
manag new focu remain busi
result greater effici profit
watch care see abbott abl realiz
potenti acquisit made avoid less
mile white took helm ceo chairman
board follow year tenur abbott date
back provid experi need handl
compani mani oper line find somewhat
worrisom white allow non-abbvie-rel
busi becom flabbi watch white
made progress profit front past
sever year still plenti room
improv abbott catch key
competitor board heavili weight
toward independ former execut
publicli trade firm chicago area particularli
pleas see stark former ceo st jude join
board expect experi lead st jude ramp
innov could posit influenc abbott
said think room improv
compens polici -- move away benchmark
involv adjust earn per share ebit
measur focus return invest capit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
abbott see strong start apr
abbott lab deliv strong first-quart perform
expect moder rais fair valu estim
adjust project key new product launch
implant cardiovert defibril ensit cardiac
map on-going adopt alin system
comprehens test panel narrow-moat compani
benefit roll-out intern innov
across portfolio well new st jude-rel product
launch delay prior acquisit
asid new product cycl pleas see
nutrit market china reach stabil although
chines legisl enact year ago
particularli far-reach certain categori
formula caus consider
competit scrambl market meet upgrad
regulatori requir addit process
obtain clearanc china food drug
administr lengthier wed expect
regulatori framework place larg
nativ manufactur multi-national competitor
receiv approv think intern pediatr
nutrit segment stem declin return
growth year
optimist adopt freestyl libr
continu glucos monitor base
enthusiast recept europ think libr
strong posit press advantag thank
headstart ahead dexcom significantli lower
price medicar reimburs type type
diabet even though offer
meaning featuresfactor calibr finger stick
addit greater accuraci still think libr
abl convert type definit penetr
type market faster
abbott growth prospect look favor
exceed expect anticip
moder rais fair valu estim reflect
optimist project firm line-up new product
launch long-await pipelin product
legaci st jude final reach commerci think
growth prospect medic devic midterm
look rosi abbott gener firm continu make
progress improv profit though adjust
oper margin fourth quarter fell slightli year
year anticip abbott resum margin expans
revenu mix shift reflect next-gen product
abbott favor posit perspect
thank wax product cycl cardiac diabet
diagnost think adopt new product
area off-set on-going soft
nutrit howev recogn even
nutrit segment finish year better shape
temper estim suggest particular
impress perform freestyl libr flash
drove diabet sale beat
expect growth strength came primarili
europ full commerci launch
product newly-establish medicar reimburs
set take effect even optimist
product line midterm
abbott cardiac devic unit also show new sign
strength st jude pipelin come fruition
expect see double-digit growth cardiac rhythm
manag electrophysiolog neuromodul
off-set weak vascular even
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
vascular product line perk thank
european launch xienc sierra coronari stent
think unlik sierra overtak
synergi stent stem loss abbott
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
